Dr. Jayagopal is a bioengineer by training with over 15 years of experience leading multidisciplinary research teams focused on therapeutic research and development, drug delivery platforms, and biomarkers for retinal diseases in industry and academia. Ash oversees research and development strategy for Opus, including the execution of IRD clinical trials and pipeline development for retinal diseases. Prior to the acquisition of Opus Genetics by Ocuphire Pharma, he served as the Chief Scientific Officer of Opus Genetics. In this role he had scientific and clinical leadership responsibility for Opus’ retinal gene therapy portfolio, including management of discovery, manufacturing, nonclinical development, and clinical development functions. Prior to Opus, he was Executive Director of Discovery Medicine at Kodiak Sciences where he supervised early-stage portfolio development, and the Head of Molecular Pharmacology and Biomarkers in Ophthalmology at Roche. His accomplishments at Roche included leadership of teams conducting discovery and IND-enabling studies for over 16 programs, including the FDA-approved therapeutic for retinal vascular disease, Vabysmo® (trademark of Genentech, Inc.), the first bispecific antibody in ophthalmology.
Prior to his career in industry, he was an Assistant Professor and NIH-funded Principal Investigator at the Vanderbilt Eye Institute, Vanderbilt University Medical Center. Ash holds a Ph.D. in Biomedical Engineering from Vanderbilt University and an M.B.A. from the Kelley School of Business at Indiana University. An author on over 40 peer-reviewed publications, he has been awarded the Roche Key Contributor Award, Dolly Green Special Scholar Award from Research to Prevent Blindness, and a Junior Faculty Award from the American Diabetes Association. He is a Fellow of the Association for Research in Vision and Ophthalmology (ARVO), and a Fellow and President of the Association for Ocular Pharmacology and Therapeutics (AOPT). He serves on the Innovation Advisory Council for Foundation Fighting Blindness and the Editorial Board of Journal of Ocular Pharmacology and Therapeutics.
What is Ashwath Jayagopal's net worth?
The estimated net worth of Ashwath Jayagopal is at least $2.60 million as of April 23rd, 2026. Dr. Jayagopal owns 509,233 shares of Opus Genetics stock worth more than $2,602,181 as of April 30th. This net worth evaluation does not reflect any other assets that Dr. Jayagopal may own. Learn More about Ashwath Jayagopal's net worth.
How do I contact Ashwath Jayagopal?
Has Ashwath Jayagopal been buying or selling shares of Opus Genetics?
During the last quarter, Ashwath Jayagopal has sold $39,142.98 of Opus Genetics stock. Most recently, Ashwath Jayagopal sold 7,542 shares of the business's stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $5.19, for a transaction totalling $39,142.98. Following the completion of the sale, the insider now directly owns 509,233 shares of the company's stock, valued at $2,642,919.27. Learn More on Ashwath Jayagopal's trading history.
Who are Opus Genetics' active insiders?
Are insiders buying or selling shares of Opus Genetics?
During the last year, Opus Genetics insiders bought shares 2 times. They purchased a total of 164,000 shares worth more than $323,890.00. During the last year, insiders at the sold shares 11 times. They sold a total of 4,073,395 shares worth more than $8,982,278.31. The most recent insider tranaction occured on April, 23rd when President Benjamin R Yerxa sold 7,470 shares worth more than $39,142.80. Insiders at Opus Genetics own 11.7% of the company.
Learn More about insider trades at Opus Genetics. Information on this page was last updated on 4/23/2026.
